Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1 platform protocol designed to evaluate various targeted agents for the
treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).